Aurobindo Pharma shares rise nearly 7 percent after Q2 results

Published On 2020-11-14 04:00 GMT   |   Update On 2020-11-14 04:01 GMT

New Delhi: Shares of Aurobindo Pharma on Thursday gained nearly 7 percent in early trade after the company reported a 26 percent increase in consolidated net profit in the second quarter ended September.

After opening in the green, the stock further jumped 6.47 percent to Rs 863.60 on the BSE.

On the NSE, shares of the company rose by 6.56 percent to Rs 864.

Aurobindo Pharma on Wednesday reported a 26 percent increase in consolidated net profit at Rs 805.65 crore in the second quarter ended September.

The company had posted a consolidated net profit of Rs 639.53 crore in the same quarter last fiscal, Aurobindo Pharma said in a regulatory filing.

Consolidated total revenue from operations during the period under review stood at Rs 6,483.44 crore as against Rs 5,600.47 crore in the corresponding quarter last fiscal, it added.

Aurobindo Pharma Managing Director N Govindarajan said: "We continue to perform well across all our key geographies and segments to report a consistent set of earnings."


Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News